Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the company's growth. The company reaffirmed its 2026 revenue guidance of $1.0 to $1.04 billion for WAKIX and plans to report clinical data for its BP-205 drug in Q4 2026. This leadership change aligns with Harmony's strategic focus on expanding its CNS pipeline, protecting WAKIX exclusivity, and pursuing growth opportunities.
Harmony Biosciences CEO transition news offers context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 12, 2026 17:11 WIB: Out of 128 priced US health stocks, 58 rose and 42 fell. Notable movers include ROIV at USD 34.70 down 2.09%, HRTX at USD 0.41 up 2.07%, and ABEO at USD 4.84 down 2.02%. Typical hold times vary from 3 to 36 days on Pluang.
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 e...
The European Commission has chosen Neo Performance Materials' Silmet 2.0 as one of 46 Strategic Projects under the EU's Critical Raw Materials Act, recognizing its importance in rare earth processing. Greenland Mines, a key shareholder in Neo, sees t...
